Vira Shield 6+VL5

Manufacturer: Novartis (Farm Animal)

Bovine Rhinotracheitis-virus Diarrhea-parainfluenza 3-respiratory Syncytial Virus Vaccine

Killed Virus

Campylobacter Fetus-leptospira Canicola-grippotyphosa-hardjo-icterohaemorrhagiae-pomona Bacterin

For Use In Animals Only

Vira Shield 6+VL5 Indications

For use in healthy breeding cattle, including pregnant cows and heifers, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis (IBR), bovine virus diarrhea (BVD Type 1 and BVD Type 2), parainfluenza Type 3 (PI₃), and bovine respiratory syncytial (BRSV) viruses and Campylobacter fetus, Leptospira canicola, grippotyphosa, hardjo, icterohaemorrhagiae, and pomona. Produced from non-cytopathic (BVD Type 1 and BVD Type 2) and cytopathic (BVD Type 1) isolates.

Adjuvant

Xtend^® SP.

Directions

Shake well before using. Administer 5 mL subcutaneously 2-4 weeks prior to breeding. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck. Revaccinate with Vira Shield^® 6 in 4-5 weeks. Revaccinate annually or as recommended by your veterinarian.

Precautions

Store out of direct sunlight at 2°-7°C (35°-45°F). DO NOT FREEZE. Use entire contents when first opened. Do not vaccinate within 60 days prior to slaughter. Transient swelling may occur at the site of injection. Milk reduction and transient depression may be observed in lactating dairy cows for 3-6 days following vaccination. Anaphylactic reactions may occur. Symptomatic treatment: Epinephrine. Contains amphotericin B, gentamicin, and thimerosal as preservatives.

U.S. Vet. License No. 303; Novartis Animal Health US, Inc., Larchwood, IA 51241 USA; ©2007 Novartis; Registered trademarks of Novartis AG

10 Doses	50 mL	307-02
50 Doses	250 mL	312-02

Nac No.

11140961